Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 2
1994 3
1995 2
1997 1
1999 1
2000 1
2001 3
2002 2
2003 1
2004 4
2005 1
2006 2
2008 6
2009 3
2011 6
2012 7
2013 4
2014 3
2015 4
2016 2
2017 1
2018 2
2019 7
2020 4
2021 1
2022 1
2023 3
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma.
Spasevska I, Sharma A, Steen CB, Josefsson SE, Blaker YN, Kolstad A, Rustad EH, Meyer S, Isaksen K, Chellappa S, Kushekhar K, Beiske K, Førsund MS, Spetalen S, Holte H, Østenstad B, Brodtkorb M, Kimby E, Olweus J, Taskén K, Newman AM, Lorenz S, Smeland EB, Alizadeh AA, Huse K, Myklebust JH. Spasevska I, et al. Among authors: ostenstad b. Blood Adv. 2023 Dec 12;7(23):7216-7230. doi: 10.1182/bloodadvances.2023010158. Blood Adv. 2023. PMID: 37695745 Free PMC article.
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group. Pfreundschuh M, et al. Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21. Lancet Oncol. 2011. PMID: 21940214 Clinical Trial.
Reply to M. Sorigue et al.
Lockmer S, Østenstad B, Hagberg H, Holte H, Wahlin BE, Wader KF, Smedby KE, Brown P, Kimby E. Lockmer S, et al. Among authors: ostenstad b. J Clin Oncol. 2019 Mar 20;37(9):759-760. doi: 10.1200/JCO.18.02362. Epub 2019 Feb 8. J Clin Oncol. 2019. PMID: 30735430 No abstract available.
High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study.
Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M, Østenstad B, Fluge Ø, Delabie J, Aarset H, Liestøl K, Holte H. Eide MB, et al. Among authors: ostenstad b. Br J Haematol. 2011 Mar;152(5):600-10. doi: 10.1111/j.1365-2141.2010.08519.x. Epub 2011 Jan 17. Br J Haematol. 2011. PMID: 21241276 Free article. Review.
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.
Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH. Josefsson SE, et al. Among authors: ostenstad b. Cancer Immunol Res. 2019 Mar;7(3):355-362. doi: 10.1158/2326-6066.CIR-18-0351. Epub 2019 Jan 18. Cancer Immunol Res. 2019. PMID: 30659053 Free PMC article.
Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up.
Pulczynski EJ, Simonsen MR, Kuittinen O, Fagerli UM, Erlanson M, Fluge Ø, Leppä S, Østenstad B, Fosså A, Eriksson M, El-Galaly T, Kuitunen H, Papworth K, Ljungqvist M, Pedersen MB, Pollari M. Pulczynski EJ, et al. Among authors: ostenstad b. Haematologica. 2024 Jul 1;109(7):2359-2363. doi: 10.3324/haematol.2024.285207. Haematologica. 2024. PMID: 38546689 Free PMC article. Clinical Trial. No abstract available.
Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas.
Kimby E, Östenstad B, Brown P, Hagberg H, Erlanson M, Holte H, Linden O, Johansson AS, Ahlgren T, Wader K, Wahlin BE, Delabie J, Sundström C; Nordic Lymphoma Group (NLG). Kimby E, et al. Among authors: ostenstad b. Leuk Lymphoma. 2015;56(9):2598-607. doi: 10.3109/10428194.2015.1014363. Epub 2015 Mar 11. Leuk Lymphoma. 2015. PMID: 25686644 Clinical Trial.
A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.
Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M. Steen CB, et al. Among authors: ostenstad b. Haematologica. 2019 Oct;104(10):e460-e464. doi: 10.3324/haematol.2018.209080. Epub 2019 Mar 7. Haematologica. 2019. PMID: 30846496 Free PMC article. Clinical Trial. No abstract available.
68 results